Adding ipatasertib to first-line paclitaxel modestly improved progression-free survival in women with triple-negative breast cancer.
Despite previously reported progression-free survival improvements with cediranib, results from the ICON6 trial failed to show a statistically significant improvement in overall survival.
Individualizing first-line sunitinib was associated with improved response and survival times among patients with metastatic renal cell carcinoma.
Adjuvant radiotherapy for diffuse large B-cell lymphoma is unnecessary for elderly patients who have PET-negative bulky disease following immunochemotherapy.
Prognostic somatic copy number alterations in diffuse large B-cell lymphoma can be detected and monitored noninvasively using ctDNA from patient plasma.
Abemaciclib plus fulvestrant was linked with improved response and PFS in patients with endocrine-resistant, HR-positive, HER2-negative metastatic breast cancer.
Palbociclib alone and in combination with endocrine therapy offers clinical benefit among women with HR-positive, HER2-negative metastatic breast cancer.
Despite toxicity, olaparib maintenance therapy is associated with improved patient-reported symptoms outcomes and improved quality-adjusted progression-free survival among patients with germline BRCA mutation-positive, platinum-sensitive relapsed serious ovarian cancer.
Adding bevacizumab to neoadjuvant chemotherapy did not improve complete macroscopic response rate or progression-free survival in women with ovarian cancer.
Platinum-sensitive ovarian cancer patients with a positive predictive AGO score who undergo a secondary debulking surgery after relapse on platinum chemotherapy experience longer progression-free survival.